The development of anticancer drugs remains slow and costly. Use of predictive biomarkers has been postulated to not only accelerate this process but also increase the odds of drug approval ([1][1]). Despite concerns about the validation of the insulin-like growth factor receptor type I (IGF-IR) as
No takes yet. Share an insight, caveat, or question.
Carden et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: